scholarly article | Q13442814 |
P356 | DOI | 10.1093/JAC/47.1.43 |
P698 | PubMed publication ID | 11152430 |
P2093 | author name string | Eriksson S | |
Norrby SR | |||
Nord CE | |||
Englund G | |||
Myhre EB | |||
Granström G | |||
Wiström J | |||
Svenungsson B | |||
Lagergren L | |||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | inpatient care | Q1431847 |
diarrhea | Q40878 | ||
P304 | page(s) | 43-50 | |
P577 | publication date | 2001-01-01 | |
P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
P1476 | title | Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study | |
P478 | volume | 47 |
Q58798841 | A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands |
Q28185605 | A randomized trial of yogurt for prevention of antibiotic-associated diarrhea |
Q36864125 | A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients |
Q40290996 | Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species |
Q37039028 | Adjuvant vancomycin for antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery. |
Q34984996 | Ageing and infection |
Q89081593 | Antibiotic Resistance Characterization of Environmental E. coli Isolated from River Mula-Mutha, Pune District, India |
Q44307285 | Antibiotic induced diarrhea and pseudomembranous colitis |
Q91998180 | Antibiotic-Induced Increase in Inflammatory Markers in Cured Infectious Spondylitis : Two Case Reports |
Q36108490 | Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials? |
Q37277087 | Antibiotic-associated diarrhea: epidemiology, trends and treatment |
Q36446885 | Antibiotic-associated diarrhoea |
Q40690828 | Antibiotic-associated diarrhoea in emergency department observation unit patients |
Q55407461 | Antibiotic-induced changes in the microbiota disrupt redox dynamics in the gut. |
Q85590502 | Antibiotica geassocieerde en Clostridium difficile geassocieerde diarree bij ouderen : Klinische les |
Q44447065 | Antibiotics conspicuously affect community profiles and richness, but not the density of bacterial cells associated with mucosa in the large and small intestines of mice |
Q42424817 | Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital |
Q38588205 | Antimicrobial susceptibility testing breakpoints and methods from BSAC to EUCAST. |
Q50025746 | Antimicrobial‐associated diarrhoea in three equine referral practices |
Q51761741 | Are self-reported gastrointestinal symptoms among older adults associated with increased intestinal permeability and psychological distress? |
Q85263911 | BSAC standardized disc susceptibility testing method (version 11) |
Q97067608 | Bifidobacterium bifidum Suppresses Gut Inflammation Caused by Repeated Antibiotic Disturbance Without Recovering Gut Microbiome Diversity in Mice |
Q42608467 | Characterization of a novel macrolide efflux gene, mef(B), found linked to sul3 in porcine Escherichia coli |
Q24536057 | Clindamycin as an antimalarial drug: review of clinical trials |
Q35759007 | Clindamycin plus quinine for treating uncomplicated falciparum malaria: a systematic review and meta-analysis |
Q44778102 | Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem |
Q36361044 | Clinical characteristics of Clostridium difficile infection in hospitalized patients with antibiotic-associated diarrhea in a university hospital in China |
Q37032807 | Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection |
Q37401597 | Clinical use of probiotics in the pediatric population |
Q39085710 | Clonal variation in high- and low-level phenotypic and genotypic mupirocin resistance of MRSA isolates in south-east London |
Q92749601 | Clostridium butyricum Modulates the Microbiome to Protect Intestinal Barrier Function in Mice with Antibiotic-Induced Dysbiosis |
Q38837137 | Clostridium difficile Enterocolitis and Reactive Arthritis: A Case Report and Review of the Literature |
Q27016320 | Clostridium difficile Infection in Children: Current State and Unanswered Questions |
Q34097514 | Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota |
Q40923400 | Clostridium difficile in Crete, Greece: epidemiology, microbiology and clinical disease |
Q36383006 | Clostridium difficile infection in hospitalized children in the United States |
Q37289567 | Clostridium difficile infection in the twenty-first century |
Q44509461 | Clostridium difficile infections related to antibiotic use and infection control facilities in two university hospitals |
Q78518492 | Clostridium difficile-associated Enteric Disease |
Q34767730 | Clostridium difficile-associated diarrhea: current strategies for diagnosis and therapy |
Q26752760 | Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections |
Q49195473 | Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). |
Q38080794 | Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) |
Q37293859 | Does Lactobacillus GG prevent antibiotic-associated diarrhea in children?: Part A: Evidence-based answer and summary |
Q38700972 | Dual-coated lactic acid bacteria: an emerging innovative technology in the field of probiotics |
Q33938275 | Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice |
Q35912695 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice |
Q41839829 | Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model |
Q34209418 | Effects of probiotics and antibiotics on the intestinal homeostasis in a computer controlled model of the large intestine |
Q51743963 | Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study |
Q35755346 | Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea - a placebo controlled double-blind randomized, multi-center study |
Q37112983 | Emerging Insights into Antibiotic-Associated Diarrhea and Clostridium difficile Infection through the Lens of Microbial Ecology |
Q36885087 | Enteral-tube-feeding diarrhoea: manipulating the colonic microbiota with probiotics and prebiotics |
Q33899721 | Epidemic Clostridium difficile strains demonstrate increased competitive fitness compared to nonepidemic isolates |
Q24562996 | Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs |
Q35922850 | Epidemiology and molecular characterization of Clostridium difficile strains from patients with diarrhea: low disease incidence and evidence of limited cross-infection in a Swedish teaching hospital |
Q83853009 | Evaluating contemporary antibiotics as a risk factor for Clostridium difficile infection in surgical trauma patients |
Q50794338 | Excess risk of Clostridium difficile infection in ovarian cancer is related to exposure to broad-spectrum antibiotics |
Q36759245 | Extended antimicrobial prophylaxis after gastric cancer surgery: a systematic review and meta-analysis |
Q35733944 | Factors influencing the development of antibiotic associated diarrhea in ED patients discharged home: risk of administering IV antibiotics |
Q34823125 | Fosmidomycin, a novel chemotherapeutic agent for malaria |
Q47856504 | Frequency of Antibiotic-Associated Diarrhea and Related Complications in Pediatric Patients Who Underwent Hypospadias Repair: a Comparative Study Using Probiotics vs Placebo |
Q35134579 | Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis |
Q28085584 | Gut microbiota as potential orchestrators of irritable bowel syndrome |
Q36531406 | Hospital Transfer Network Structure as a Risk Factor for Clostridium difficile Infection |
Q42136589 | Human intestinal microbiota gene risk factors for antibiotic-associated diarrhea: perspectives for prevention. Risk factors for antibiotic-associated diarrhea |
Q98164075 | Identification of Simplified Microbial Communities That Inhibit Clostridioides difficile Infection through Dilution/Extinction |
Q43828599 | Impact of hospital‐acquired Clostridium difficile |
Q42261294 | In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile |
Q55539731 | Infection Prophylaxis Update. |
Q34761329 | Infection in the chronically critically ill: unique risk profile in a newly defined population |
Q59442204 | Les diarrhées post-antibiotiques |
Q36832446 | Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development |
Q42778196 | Managing antibiotic associated diarrhoea |
Q33222511 | Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea |
Q38101378 | Metabolic plasticity for isoprenoid biosynthesis in bacteria |
Q35862915 | Novel approaches to treating Clostridium difficile-associated colitis. |
Q61307050 | Omadacycline Gut Microbiome Exposure Does Not Induce Clostridium difficile Proliferation or Toxin Production in a Model That Simulates the Proximal, Medial, and Distal Human Colon |
Q40101500 | Pathogenicity Locus, Core Genome, and Accessory Gene Contributions to Clostridium difficile Virulence |
Q28546491 | Patterns of Adverse Drug Reactions in Different Age Groups: Analysis of Spontaneous Reports by Community Pharmacists |
Q33915343 | Postoperative Clostridium difficile-associated diarrhea |
Q44663914 | Prevalence of diarrhea at a university hospital and association with modifiable risk factors |
Q42631832 | Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections |
Q38811781 | Probiotic approach to prevent antibiotic resistance. |
Q39265808 | Probiotic treatment for the prevention of antibiotic-associated diarrhoea in geriatric patients: a multicentre randomised controlled pilot study |
Q42470900 | Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials |
Q46288228 | Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis |
Q91644124 | Probiotics for the prevention of pediatric antibiotic-associated diarrhea |
Q24186991 | Probiotics for the prevention of pediatric antibiotic-associated diarrhea |
Q24235039 | Probiotics for the prevention of pediatric antibiotic-associated diarrhea |
Q24245196 | Probiotics for the prevention of pediatric antibiotic-associated diarrhea |
Q24247364 | Probiotics for the prevention of pediatric antibiotic-associated diarrhea |
Q37892873 | Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection |
Q35056944 | Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study |
Q37286025 | Prophylactic antibiotics for clean, non-implant plastic surgery: what is the evidence? |
Q44637882 | Pseudomembranous colitis during antibiotic therapy |
Q38654043 | Randomized, Controlled, Crossover trial of Prevention of Clindamycin-Induced Gastrointestinal Signs Using a Synbiotic in Healthy Research Cats. |
Q26767079 | Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection |
Q37014790 | Rectal nitric oxide gas and stool cytokine levels during the course of infectious gastroenteritis |
Q35199060 | Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile. |
Q45324761 | Risk factors for seasonal influenza virus detection in stools of patients consulting in general practice for acute respiratory infections in France, 2014-2016. |
Q34549108 | Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies |
Q34094620 | Role of Lactobacillus in the prevention of antibiotic-associated diarrhea: a meta-analysis |
Q38775801 | Role of antimicrobials in the treatment of adult patients presenting to the emergency department with acute gastroenteritis - A mini review. |
Q38200538 | Role of doxycycline in Clostridium difficile infection acquisition |
Q37355090 | Saccharomyces boulardii in childhood |
Q28237525 | Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial |
Q38376098 | Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial |
Q36909136 | Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem |
Q36538752 | Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses |
Q47149248 | Scientific Opinion on the substantiation of a health claim related to fermented milk containing Lactobacillus casei DN-114 001 plus yoghurt symbiosis (Actimel®), and reduction of Clostridium difficile toxins in the gut of patients receiving antibi... |
Q35616704 | Severe acute diarrhea |
Q37068231 | Stool therapy may become a preferred treatment of recurrentClostridium difficile? |
Q64083709 | Surveys of parents and clinicians concerning the minimally important difference of probiotic therapy for prevention of paediatric antibiotic-associated diarrhoea |
Q34565061 | Systematic review of antimicrobial drug prescribing in hospitals. |
Q35771988 | Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. |
Q34487166 | Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea |
Q37825531 | Systematic review: Clostridium difficile and inflammatory bowel disease. |
Q90224285 | The Potential Impact of Probiotics on the Gut Microbiome of Athletes |
Q28750385 | The changing epidemiology of Clostridium difficile infections |
Q39182081 | The effect of polydextrose and probiotic lactobacilli in a Clostridium difficile-infected human colonic model |
Q36066272 | The plastid-derived organelle of protozoan human parasites as a target of established and emerging drugs |
Q35861325 | The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens |
Q33927147 | Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. |
Q57779043 | Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics |
Q40092648 | Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review. |
Q36373108 | Treatment of bacterial skin infections in ED observation units: factors influencing prescribing practice |
Q37333236 | What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? |
Search more.